- Current report filing (8-K)
April 27 2010 - 9:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): April 27, 2010
ADVENTRX Pharmaceuticals,
Inc.
(Exact name of registrant as
specified in its charter)
|
|
|
|
|
Delaware
|
|
001-32157
|
|
84-1318182
|
(State or other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
6725 Mesa Ridge Road, Suite
100
San Diego, CA
|
|
92121
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code:
(858) 552-0866
|
N/A
|
(Former name or former address if changed since last report.)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 8.01. Other Events.
On April 27, 2010, ADVENTRX
Pharmaceuticals, Inc. issued a press release announcing its plans to resubmit
its new drug application for ANX-530 (vinorelbine injectable emulsion), or
Exelbine™, to the U.S. Food and Drug Administration in the fourth quarter
of 2010. The press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
Item 9.01. Financial
Statements and Exhibits.
(d) Exhibits.
The list of
exhibits called for by this Item is incorporated by reference to the
Exhibit Index filed with this report.
2
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
|
|
|
ADVENTRX Pharmaceuticals,
Inc.
|
|
|
|
Dated: April 27, 2010
|
By:
|
/s/ Patrick Keran
|
|
|
Name: Patrick Keran
Title: President and Chief Operating Officer
|
3
EXHIBIT INDEX
|
|
|
Exhibit No.
|
|
Description
|
99.1
|
|
Press Release, dated April 27, 2010
|
4
Adventrx (AMEX:ANX)
Historical Stock Chart
From May 2024 to Jun 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2023 to Jun 2024